Gsa Capital Partners LLP Pds Biotechnology Corp Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding PDSB
# of Institutions
59Shares Held
4.22MCall Options Held
170KPut Options Held
6.7K-
Vanguard Group Inc Valley Forge, PA1.51MShares$2.02 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$652,5350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA417KShares$559,0700.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA247KShares$330,9490.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il220KShares$295,0880.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $38.1M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...